EBS vs. INVA, OPK, IRWD, LXRX, VNDA, XOMA, AGEN, CDXS, ACHV, and RIGL
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Agenus (AGEN), Codexis (CDXS), Achieve Life Sciences (ACHV), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.
Emergent BioSolutions (NYSE:EBS) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
Emergent BioSolutions received 117 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 66.45% of users gave Emergent BioSolutions an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has lower revenue, but higher earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions currently has a consensus price target of $5.00, suggesting a potential upside of 7.30%. Given Emergent BioSolutions' higher possible upside, equities research analysts clearly believe Emergent BioSolutions is more favorable than Innoviva.
Innoviva has a net margin of 58.21% compared to Emergent BioSolutions' net margin of -47.68%. Innoviva's return on equity of 28.94% beat Emergent BioSolutions' return on equity.
In the previous week, Innoviva had 3 more articles in the media than Emergent BioSolutions. MarketBeat recorded 5 mentions for Innoviva and 2 mentions for Emergent BioSolutions. Innoviva's average media sentiment score of 1.75 beat Emergent BioSolutions' score of 0.50 indicating that Innoviva is being referred to more favorably in the news media.
78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by company insiders. Comparatively, 1.4% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Emergent BioSolutions has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Summary
Innoviva beats Emergent BioSolutions on 11 of the 17 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
